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ABSTRACT
Major histocompatibility complex (MHC) class I molecules present antigenic 
peptides to cytotoxic T cells. During an adaptive immune response, MHC molecules are 
regulated by several mechanisms including lipopolysaccharide (LPS) and interferon 
gamma (IFN-g). However, it is unclear whether the serine protease cathepsin G 
(CatG), which is generally secreted by neutrophils at the site of inflammation, 
might regulate MHC I molecules. We identified CatG, and to a higher extend CatG 
and lactoferrin (LF), as an exogenous regulator of cell surface MHC I expression of 
immune cells and glioblastoma stem cells. In addition, levels of MHC I molecules 
are reduced on dendritic cells from CatG deficient mice compared to their wild type 
counterparts. Furthermore, cell surface CatG on immune cells, including T cells, B 
cells, and NK cells triggers MHC I on THP-1 monocytes suggesting a novel mechanism 
for CatG to facilitate intercellular communication between infiltrating cells and the 
respective target cell. Subsequently, our findings highlight the pivotal role of CatG 
as a checkpoint protease which might force target cells to display their intracellular 
MHC I:antigen repertoire.
INTRODUCTION
Foreign antigens are presented by major 
histocompatibility complex (MHC) molecules to activate 
T cells. The proteasome degrades cytosolic antigens 
and the resulting antigenic peptides are directed into 
the endoplasmatic reticulum (ER), further processed 
by exopeptidases, loaded to MHC I molecules, and the 
MHC I-peptide complex is presented on the cell surface 
to cytotoxic T lymphocytes (CTLs) [1]. In professional 
antigen presenting cells (APCs) a cross talk between endo- 
and exogenous antigens and MHC I-mediated antigen 
presentation exists. For instance, endocytosed cell surface 
MHC I molecules can be recycled, some ER resident MHC 
I molecules, which traffic to the trans-Golgi network, 
can be forced to the endocytic compartment, or MHC 
I molecules can be partially sorted to the phagosome. 
In these different compartments, MHC I molecules are 
possibly loaded with a new set of exogenous/endocytic-
derived antigenic peptides for CTLs inspection [2-5]. 
Tumor cells downregulate expression of MHC I 
molecules to escape detection by CTLs, a mechanism 
known as immune evasion [6]. Glioblastoma cells, 
representing the most aggressive tumor in the brain, 
avoid the presentation of tumor-associated antigens and 
subsequent activation of CTLs by partly downregulating 
MHC I [7]. In order to evade detection by natural killer 
(NK) cells, glioblastoma cells maintain a limited set of 
MHC I at the cell surface [8]. The question remains how 
MHC I molecules could be restored on the cell surface 
to present tumorigenic antigens for recognition by CTLs.
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During inflammation, polymorphonuclear 
neutrophils secrete different serine proteases, such 
as cathepsin G (CatG), neutrophil elastase (NE), and 
proteinase 3 (PR3), to promote an immune response [9]. 
Thereby secreted CatG can bind to the cell surface of 
T cells, B cells, and NK cells as well as activated pro-
inflammatory monocytes [10, 11] and perform several 
physiological roles, including lymphocyte stimulation 
[12], generation of angiotensin II [13], or inactivation of 
the chemokine stromal cell-derived factor 1 (SDF-1) [11]. 
Furthermore, CatG bound on B cells can be internalized 
to the endocytic compartment to broaden their protease 
repertoire which is important for antigen processing [14]. 
However, it is not known whether exogenous CatG may 
regulate antigen presentation via MHC I on the target cell.
Lactoferrin (LF) is a multifunctional protein, 
contained in excretory fluids of mammals and secondary 
granules of neutrophils, playing a key role in innate and 
adaptive immunity [15]. Interestingly, LF was found to 
inhibit growth of glioblastoma cells, which form one of 
the most aggressive tumors, by a direct inhibition of the 
cell cycle [16]. However, until now, no data are available 
regarding LF as a possible enhancer of MHC class I cell 
surface expression. We found that LF enhances CatG 
activity and lowers its substrate specificity [17]. Therefore, 
investigation on potential additive or synergistic action by 
LF and CatG in regulation of MHC I is of interest.
Recently, we found that endogenous CatG, resident 
in the endocytic compartment, proteolytically degrades 
MHC I molecules [18]. Here, we demonstrate that 
exogenous CatG upregulates MHC I on the cell surface 
of different cell types, most likely, via deactivation of the 
protease-activated receptor 1 (PAR1). CatG-mediated 
upregulation of MHC I is further enhanced by LF in 
peripheral blood mononuclear cells (PBMCs) and a B cell 
line but not in glioblastoma stem cells. PBMCs, consisting, 
among others, of T cells, B cells, and NK cells and exhibit 
CatG on the cell surface [10] which, induced cell surface 
expression of MHC I molecules in THP-1. Moreover, 
dendritic cells (DCs) from CatG-deficient mice harbor less 
MHC I compared to their control counterparts. These data 
suggest that exogenous CatG regulates cell surface MHC 
I expression to support monitoring the intracellular status 
of target cells. 
 RESULTS
The proteolytic activity of exogenous CatG 
elevates cell surface expression of MHC I
CatG is secreted by neutophils at the site of 
inflammation to promote a rapid immune response. As a 
result, CatG can bind to the cell surface of several types 
of immune cells [9-11]. This raises the question whether 
exogenous CatG might induce the expression of accessory 
molecules on target cells. To this end, human peripheral 
blood mononuclear cells (PBMCs) were incubated with 
purified human CatG and cell surface molecules were 
analyzed by flow cytometry. We found that MHC I was 
upregulated by active CatG, but not by heat inactivated 
CatG (Figure 1A), which was added to the assay to exclude 
the presence of a non-protease contamination of the 
CatG preparation. In another control experiment, several 
different inhibitors were used to verify the specificity of 
CatG. The inhibitor panel included the reversible CatG 
inhibitor, CatG inhibitor I, and the irreversible CatG 
inhibitor (SucVPF) which reduced CatG-induced MHC I 
expression, compared to the cysteine protease inhibitor, 
E64 or the aspartic protease inhibitor, PepA which did not 
affect CatG activity (Supp. data S1). Thus, the proteolytic 
activity of CatG provokes an increase of MHC I on the 
cell surface of PBMCs.
Protease-activated receptors (PARs) belong to 
the family of G-protein-coupled receptors. CatG, for 
instance, cleaves PAR1-4 which leads to the activation 
of the receptor and followed by a wide range of cellular 
functions. However, CatG can also inactivate (disarm) 
PAR depending on the cleavage motif thereby switching 
on different pathways or disable signaling [19, 20]. To 
investigate the potential mechanism of CatG-induced 
MHC I expression, human acute monocytic leukemia 
cell line (THP-1), which only expresses PAR1 and PAR4 
[21], was incubated with the PAR1 antagonist (FR171113, 
FR) [22] or the PAR4 antagonist (tcY-NH2) [23] in the 
presence or absence of CatG. FR increased cell surface 
MHC I expression and was even further enhanced by 
adding CatG, compared to the PAR4 antagonist tTcY-NH2 
which had no effect on cell surface MHC I (Supp. Data 
S2). In the next set of experiments, PBMCs from young 
or elderly donors, which do express PAR1 (Supp. Data 
S3), were used to determine possible differences in MHC 
I regulation depending on age. PBMC were incubated with 
CatG or the respective controls as described before. While 
CatG induced an increase of MHC I on the cell surface of 
PBMCs no significant differences between the two groups 
were detected (Figure 1B). Additionally, incubation 
of PBMCs with the PAR1 antagonist FR resulted in a 
similar upregulation of MHC I in young donors, whereas 
recombinant CatS or the vehicle control DMSO had no 
effect. Taken together, these results show that CatG-
mediated abundance of MHC I are most likely due to the 
deactivation of PAR1.
Lactoferrin-mediated enhancement of CatG 
activity elevates MHC I
Recently, we found that physiological concentration 
of lactoferrin (LF) enhanced the activity and broadens the 
substrate selectivity of CatG [17]. Having this in mind, 
we sought to determine whether the expression of MHC I 
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Figure 1: Analysis of cell surface expression of MHC I molecules. A. Human peripheral blood mononuclear cells (PBMCs) were 
incubated for 6 h with either CatG or heat inactivated CatG and the MHC I cell surface expression was analyzed by using flow cytometry. 
Data of one representative experiment out of five is shown. B. PBMCs were obtained from young and elderly donors and were incubated 
with CatG, CatS, FR, or the respective inhibitor. Cells were gated for lymphocytes. Data were normalized and considered significant at 
p < 0.05 (*), p < 0.0001 (****), and not significant at p > 0.05 (n.s.) by using the unpaired two-tailed Student’s t test. Error bars indicate 
the standard error of the median (SEM). A total of ten experiments (n = 10 young donors; n = 10 elderly donors) were performed. inh. = 
inhibitor.
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can be further elevated by using CatG in combination with 
LF. CatG initiated an upregulation of MHC I at the cell 
surface of PBMCs as expected (Figure 2A). Strikingly, 
levels of MHC I were further increased by the combined 
action of CatG and LF. This is in contrast to the B cell line 
BSM where CatG did not significantly alter cell surface 
expression of MHC I. However, CatG along with LF 
triggered an increase of MHC I (Figure 2B). Collectively, 
these findings identify LF as an enhancer of CatG-induced 
upregulation of MHC I.
Figure 2: Detection of CatG-mediated enhancement of cell surface MHC I under the control of lactoferrin (LF). A. 
PBMCs or B. the B cell line (BSM) were incubated with CatG, CatG with LF, CatG with LF and CatG inhibitor (CatGinh.), CatG with 
LF and DMSO, or CatG with CatGinh. for 6h at 37°C. Cell surface expression of MHC I was determined by flow cytometry. Seven 
independent experiments were performed for PBMCs (n = 7) and six for BSM (n = 6).
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Figure 3: CatG induced cell surface expression of MHC I in spheres-cultured stem cell-enriched glioblastoma cell 
population (SC). A. SC35, SC38, and SC40 were incubated with CatG, LF, CatGinh., DMSO, CatG with LF, CatG with LF and CatG 
inhibitor (CatGinh.), CatG with LF and DMSO, or CatG with CatGinh. for 24h at 37°C. Cell surface expression of A. PAR1 or B. MHC I 
was determined by flow cytometry. All values were normalized to the isotype control. Eight independent experiments were performed (n = 
8) and summarized in a bar diagram. SC35, SC38, and SC40 were treated with different proteases (CatG, CatS, NE, PAR3, and thrombin) 
for 24h at 37°C and levels of PAR1 C. or MHC I D. were analyzed by flow cytometry. Nine independent experiments were performed (n = 
9) and values were normalized to the isotype control.
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CatG increases MHC I on sphere-cultured stem 
cell-enriched cell populations (SCs)
Next, we addressed the question whether CatG might 
upregulate MHC I in primary patient-derived glioblastoma 
stem cells. To this end, sphere-cultured stem cell-enriched 
cell populations (SCs) from three different glioblastoma 
patients (SC35, SC38, and SC40) were incubated with 
CatG and levels of PAR1 and MHC I were assessed by 
flow cytometry. While PAR1 was downregulated in all SCs 
tested (Figure 3A), MHC I was significantly upregulated 
in SC35 and SC40 and glioblastoma cell line (U87) but 
not in SC38 (Figure 3B and Supp. Data S4). Notably, 
SC35, SC38, and SC40 did not harbor PAR2, PAR3, and 
PAR4 at the cell surface (Supp. Data S5 to S7). Although 
CatS, NE, PR3, and thrombin downregulated PAR1 these 
proteases did not significantly alter expression of MHC 
I in SC35, SC38, and SC40 (Figure 3C and 3D), which 
might account for their different proteolytic cleavage 
sites. Taken together, CatG can induce MHC I in primary 
patient-derived glioblastoma stem cells. 
Immune cells force target cells to display their 
MHC I at the cell surface
To ascertain the physiological relevance of the 
CatG-induced increase of MHC cell surface expression, 
we co-cultured freshly isolated PBMCs with THP-
1. PBMCs harbor T cells, NK cells, activated pro-
inflammatory monocytes, and B cells, altogether known to 
bind CatG to their cell surfaces [10, 11, 24]. The presence 
of cell surface CatG on PBMCs was confirmed by a CatG 
specific antibody and flow cytometry (Supp. Data S8). 
CellTrace Violet-labeled THP-1 cells showed abundant 
levels of MHC I, when co-cultured with PBMCs, and this 
effect was abrogated by using the CatG inhibitor (Figure 
4A). Moreover, phorbol 12-myristate 13-acetate (PMA), 
which is known to induce CatG secretion in granulocytes 
[25], provokes an increase of CatG and MHC I on PBMCs 
(Supp. Data S9) as well as in activated platelets (Supp. 
Data S10), and CatG enhances the secretion of IFN-g 
(Supp. Data S11). 
Both exogenous and cell surface bound CatG were 
Figure 4: Functional assay for CatG-mediated enhancement of cell surface MHC I molecules. A. PBMCs were co-cultured 
with THP-1. To trace THP-1 cells in co-culture with PBMCs, THP-1 were permanently labeled with CellTrace Violet cytoskeleton dye. Cell 
surface levels of MHC I were analyzed. Three independent experiments with similar results were performed. B. Spleen DCs from wild-type 
(WT) and CatG-/- mice were analyzed for their MHC I cell surface expression. Data from one of two independent experiments is shown (P 
< 0.05; median MFI WT 634, CatG-/- 433, n = 4/genotype).
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responsible for upregulation of MHC I and might facilitate 
communication between immune cells. In order to test this 
hypothesis under physiological conditions, we analyzed 
the cell surface expression of MHC I in CatG deficient 
professional antigen presenting cells such as dendritic 
cells (DCs). Splenocytes were isolated from either CatG-
deficient (CatG-/-) or control wild-type (WT) mice and 
cell surface expression of MHC I was analyzed in CD11c+-
DCs. We detected reduced levels of cell surface MHC I in 
CD11c+-DCs isolated from CatG-/- mice compared to their 
WT counterparts (Figure 4B). This reduction of MHC I 
can be restored by incubating DCs from CatG deficient 
mice with CatG (Supp. Data S12). Thus, the absence of 
CatG in vivo alters levels of MHC I in DCs. 
DISCUSSION
The data provided, demonstrate that exogenous 
CatG upregulates MHC I on the cell surface of different 
cell types and the concert action of LF and CatG revealed 
further upregulation of MHC class I antigens on PBMCs 
and the B cell line BSM but not on glioblastoma stem 
cells. Furthermore, PBMCs, which exhibit CatG on the 
cell surface, induce cell surface expression of MHC I 
molecules on THP-1, which explains the finding why DCs 
from CatG-deficient mice harbor less MHC I at the cell 
surface then DCs from wild type mice. 
Our findings suggest the following scenario 
regarding a novel role for CatG in controlling cell surface 
expression of MHC I. CatG is a potent chymotrypsin-like 
serine protease produced and released by neutrophils and 
contributes to killing microbes as well as processing host 
proteins, including extracellular matrix and cell surface 
receptors [26, 27]. Free CatG activity is rapidly inhibited 
by secreted plasma serpins such as alpha1-antitrypsin, 
anti-chymotrypsin, and secretory leukocyte protease 
inhibitor (SLPI) [28, 29]. Similarly, intracellular granule 
leakage of CatG within the neutrophil cytoplasm is rapidly 
inhibited by Serpinb1 to prevent neutrophil death [30]. 
In contrast, cell-surface bound CatG cannot be reached 
by these large inhibitors due to steric hindrance [24]. T 
cells, NK cells, and B cells can bind CatG to their cell 
surface [10, 11], where CatG retains its activity. These 
immune cells communicate with antigen presenting 
cells (APCs) and generate an excessive proteolytic 
microenvironment between CatG and cell-cell contact 
side, which provokes an increased expression of MHC 
molecules on APCs in a mechanism that might synergize 
with inhibition of protease-activated receptor 1 (PAR1) 
signaling. As a result, cytotoxic T cells might be activated 
as demonstrated in Supp. data S11. Alternatively, APCs 
may be in contact with free CatG at sites of inflammation 
where proteases are in excess of their anti-protease 
shield. While the PARs activating protease (thrombin) 
and tcY-NH2 did not alter levels of MHC I, CatG and the 
PAR1 antagonist FR enhanced cell surface expression 
of MHC I by using PBMCs as target cells. Thus, CatG-
mediated induction of MHC expression might depend 
on an alternative PAR1 signaling pathway since PAR1 
probably slows down MHC I expression. Glioblastoma 
stem cells partly down modulate their MHC I cell surface 
expression and infiltrate to the surrounding brain tissue 
thereby escape immune recognition [7]. We found that 
CatG also upregulates MHC I on glioblastoma stem cells 
(SCs) which is certainly important for CTL recognition. 
However, glioblastoma cells secrete protease inhibitors 
[31] which can diminish the proteolytic activity of CatG 
and might support the immune evasion of glioblastoma 
stem cells. 
In addition, the presented data provide further 
evidence for cooperation of LF and CatG in innate 
immunity. According to the recent report, we demonstrate 
the augmentation of the enzymatic activity of CatG by 
LF [17]. Here, the results precisely indicate an enhancing 
effect of LF to CatG in upregulation of MHC I at the 
cell surface of PBMCs. Although LF or CatG alone do 
not affect MHC class I expression to the B cell line BSM 
but when they act synergistically MHC I expression was 
enhanced. 
In conclusion, we demonstrate that CatG effectively 
upregulates cell surface MHC I suggesting that CatG is 
essential for post-transcriptional regulation of MHC I 
molecules and for intercellular communication between 
immune cells and target cells.
MATERIALS AND METHODS
Animals
Mice deficient in CatG (CatG-/-, Ctsgtm1Ley) in 
C57BL6 background (Christine Pham, Washington 
University, St Louis, MO, USA) were co-housed and 
age- and sex-matched C57BL/6J wild-type (WT) mice 
were used as controls. Animal studies were approved by 
the Cantonal Veterinary Office of Bern and conducted 
in accordance with the Swiss federal legislation on 
animal welfare. Mouse splenocytes were incubated with 
labeled antibodies against CD11c-PE (clone N418), 
CD45-PerCP (clone 30-F11), MHC-I-APC (clone 
AF6-88.5) (BioLegend, San Diego, CA, USA) and 
analyzed by flow cytometry on a FACSCalibur (BD 
Biosciences, Minneapolis, MN, USA). Relative mean 
fluorescence intensity (MFI) of MHC-I on dendritic cells 
(CD45+CD11c+) was determined using FlowJo (Tree Star, 
Inc., Ashland, OR, USA) and MFI of MHC-I from 4 mice/
genotype was analyzed by Mann Whitney U test using 
Prism 6.0c (GraphPad. San Diego, CA, USA).
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Assessment of MHC I surface expression on THP-
1 cells
THP-1 cell line [32] was cultured in RPMI 1640 
medium supplemented with 10% fetal bovine serum 
(FBS) and antibiotics. Cells were washed with PBS pH 
7.4 and incubated with either the protease-activated 
receptor 1 (PAR1) antagonist, FR171113 (10 µM, 
Tocris, Bristol, UK) [22], or PAR4 antagonist, (trans-
Cinnamoyl)-YPGKF-NH2 (tcY-NH2, 10 µM, Tocris) [23] 
with or without CatG for 6 h at 37°C. DMSO served as a 
vehicle control. Subsequently, cells were washed in PBS 
and stained with anti-HLA-ABC-APC (clone W6/32; 
eBioscience, San Diego, California, USA) diluted in 
blocking buffer (1% FBS in PBS) for 30 min at 4°C. After 
two wash steps, cells were fixed in PBS containing 2% 
paraformaldehyde (PFA) and subsequently measured by a 
BD Canto II cytometer (Franklin Lakes, NJ, USA). Data 
were acquired and analyzed using FlowJo software (Tree 
Star, Inc., Ashland, OR, USA).
CatG-induced MHC I cell surface expression in 
PBMCs
B cell line (BSM) or cryopreserved PBMCs from 
healthy donors (young, 18-25 years and elderly, 59-70 
years) were used for the 6h assay. PBMCs (2x106 cells/
ml) were incubated with CatG (8 µg/ml; from human 
neutrophils, Enzo, Life Sciences or BioCentrum Ltd., 
Krakow, Poland or from human sputum, Sigma-Aldrich, 
München, Germany), heat inactivated CatG (98°C for 15 
min), recombinant CatS (0.1 µg/ml, Enzo, Life Sciences), 
or human recombinant LF from rice (250 μg/ml, 
MyBioSource, San Diego, CA, USA). To determine CatG 
specificity, CatG was preincubated with CatG inhibitor I 
(100 µM, Calbiochem, Schwalbach, Germany), Suc-Val-
Pro-PheP (OPh)2 (Suc-VPF, 100 µM; Jozef Oleksyszyn, 
Faculty of Chemistry, Wroclaw University of Technology, 
Wroclaw, Poland), or the cysteine protease inhibitor E64 
(100 µM, Enzo Life Sciences). In a separate experiment, 
PBMCs were incubated with PAR1 antagonist, FR171113 
(10 mM, Tocris) for 6 h at 37°C. DMSO served as a 
vehicle control. Cells were washed in PBS containing 1% 
FBS and stained with anti-HLA-ABC-APC (clone W6/32; 
eBioscience) or the isotype control (mouse IgG2a APC, 
eBioscience) for 30 min at 4°C and cells were measured 
by FACSCalibur (BD Biosciences). Separately, cells were 
extracellular stained with anti-human PAR1-PE (25 ug/
ml, R&D Systems, Abingdon, UK) or isotype control 
(mouse IgG2B, PE conjugated antibody, R&D Systems, 
Abingdon, UK) and analyzed by flow cytometry. Data 
were acquired and analyzed using FlowJo software (Tree 
Star). Bar diagram and statistical analysis were done 
by GraphPad Prism 4 (GraphPad Software, Inc., San 
Diego, CA, USA). Use of PBMCs for in vitro studies is 
in accordance with the local ethics committee (approved 
proposal # 327/14).
Induction of MHC I expression in THP-1 by 
PBMCs
THP-1 cell line was cultured in RPMI 1640 medium 
supplemented with 10% FBS and antibiotics. Cells were 
washed with PBS pH 7.4. THP-1 cells were permanently 
labeled by using the CellTrace Violet Cell proliferation 
kit (Invitrogen, Carlsbad, CA, USA) according to the 
manufacturer’s protocol in order to allow identification 
of THP-1 cells after co-culture. 100,000 labeled THP-1 
and 20,000 freshly isolated PBMCs were co-cultured in 
serum-free RPMI medium in the presence or absence of 
the CatG-inhibitor (10µM or l00µM, Calbiochem) for 
24 h. Then cells were stained with anti-HLA-ABC-APC 
or anti-HLA-DR-PE and subjected to flow cytometry as 
described above. Cells positive for CellTrace Violet were 
gated and analyzed. Studies involving human material 
were reviewed and approved by the University of Ulm 
Institutional Review Board, and individuals and/or their 
legal guardians provided written informed consent prior 
to donating blood. Use of PBMCs for in vitro studies is 
in accordance with the local ethics committee (approved 
proposal # 327/14).
Glioblastoma cell line
Human glioblastoma cell line U87-MG (U87, 
American Type Culture Collection, Manassas, VA, USA) 
were cultured in DMEM supplemented with 10% FBS 
and 1% penicillin (120 mg/ml)/streptomycin (120 mg/ml) 
(Life Technologies). 
Sphere-cultured stem cell-enriched glioblastoma 
cell populations (SCs)
Astrocytoma grade IV tissue from three different 
patients (No. 35, 38, or 40) was minced, washed in 
PBS, and incubated with TrypLE Express (Gibco, 
Life Technologies). Cells were filtered and cultured 
in DMEM/F-12 medium (Gibco, Life Technologies) 
containing L-glutamine, 0.01% (v/v) epidermal growth 
factor (EGF, Biomol GmbH, Hamburg, Germany), 0.04% 
(v/v) fibroblast growth factor (FGF, Miltenyi Biotec, 
Bergisch Gladbach, Germany), 1% (v/v) B27 (Gibco, Life 
Technologies), 2% Fungizone (Gibco, Life Technologies), 
1% penicillin (120 mg/ml)/streptomycin (120 mg/ml) (Life 
Technologies) [33]. These cells are herein determined 
as a sphere-cultured stem cell-enriched glioblastoma 
cell populations (SCs). Stem cell and differentiation 
markers were expressed accordingly [34]. Use of SCs 
is in accordance with the local ethics committee at Ulm 
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University (# 162/10).
CatG-induced MHC I expression in SCs
Cells were incubated with CatG, CatG with CatG 
inhibitor I (50 µM), CatG with lactoferrin (LF, 250 mg/
ml ~3.27 mM; from rice, MyBioSource, San Diego, 
CA, USA), bovine thrombin (8 µg/ml, Sigma-Aldrich), 
NE (8 µg/ml, Elastin Products Company, Owensville, 
MO, USA), PR3 (8 µg/ml, Elastin Products Company, 
Owensville, MO, USA), CatG and LF with CatG 
inhibitor I, or CatG and LF with DMSO for 24 h at 37°C. 
Cell surface MHC I or PAR1 (anti-human PAR1, PE 
conjugated, monoclonal mouse IgG2B, R&D Systems, 
Abingdon, UK) was determined by flow cytometry as 
described above.
Statistical analysis
Data were depicted as median ± standard error of 
the median (S.E.M.) and statistical analysis was performed 
using the unpaired, two-tailed Student’s t-test (Prism 4, 
GraphPad Software, La Jolla, CA, USA).
Abbreviations
APCs, antigen-presenting cells; BSM, B cell line 
(B-lymphoblastoid cells); Cat, cathepsin; DC, dendritic 
cell; ER, endoplasmatic reticulum; HLA, human leukocyte 
antigen; MFI, mean fluorescence intensity; MHC, major 
histocompatibility complex; PARs, protease-activated 
receptors; PBMCs, peripheral blood mononuclear cells; 
PMA, phorbol 12-myristate 13-acetate; SucVPF, Suc-
Val-Pro-PheP (OPh)2; THP-1, human acute monocytic 
leukemia cell line
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